S
Saveri Bhattacharya
Researcher at Thomas Jefferson University
Publications - 12
Citations - 264
Saveri Bhattacharya is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 7, co-authored 11 publications receiving 190 citations. Previous affiliations of Saveri Bhattacharya include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.
TL;DR: The classification of hormone receptor status and the various endocrine treatment strategies are described and opportunities for personalization of care are illustrated.
Journal Article
HSP90 inhibitors in lung cancer: promise still unfulfilled.
TL;DR: This review discusses the development and the preclinical and clinical profiles of some of the HSP90 inhibitors that may help to improve the targeted treatment of NSCLC.
Journal ArticleDOI
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.
TL;DR: The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis and efforts to target this mutation over the last two decades have been unsuccessful.
Journal ArticleDOI
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Zhong Ye,Chun Wang,Shaogui Wan,Zhaomei Mu,Zhenchao Zhang,Maysa M. Abu-Khalaf,Frederick M. Fellin,Daniel P. Silver,Manish Neupane,Rebecca Jaslow,Saveri Bhattacharya,Theodore N. Tsangaris,Inna Chervoneva,Adam C. Berger,Laura Austin,Juan P. Palazzo,Ronald E. Myers,Neha Pancholy,Darayus Toorkey,Kaelan Yao,Max Krall,Xiuling Li,Xiaobing Chen,Xiuhong Fu,Jinliang Xing,Lifang Hou,Qiang Wei,Bingshan Li,Massimo Cristofanilli,Hushan Yang +29 more
TL;DR: CTC and total ccf DNA levels were individually and jointly associated with PFS and OS in MBC patients and suggested that the inconsistency between CTC level and outcome in some patients could possibly be explained by ccfDNA level.
Journal ArticleDOI
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Chun Wang,Zhaomei Mu,Zhong Ye,Zhenchao Zhang,Maysa M. Abu-Khalaf,Daniel P. Silver,Juan P. Palazzo,Geetha Jagannathan,Frederick M. Fellin,Saveri Bhattacharya,Rebecca Jaslow,Theodore N. Tsangaris,Adam C. Berger,Manish Neupane,Terrence P. Cescon,Ana Maria Lopez,Kaelan Yao,Weelic Chong,Brian Lu,Ronald E. Myers,Lifang Hou,Qiang Wei,Bingshan Li,Massimo Cristofanilli,Hushan Yang +24 more
TL;DR: In advanced-stage breast cancer patients with tHER2 − tumors, cHER2 status has the potential to guide the use of anti-HER2 targeted therapy in patients with high-risk c HER2.